Share on StockTwits

GlaxoSmithKline faces new allegations that it bribed Syrian doctors and officials to boost sales of its medicines, following recent accusations of corruption in its non-prescription business in the country. GSK, one of the few big firms still supplying drugs in Syria, said on Monday it would investigate the new claims involving its own staff and local distributors. The company added it had suspended relations with its Syrian distributors pending results of the probe.

“Exclusive: GlaxoSmithKline Faces Fresh Drug Bribery Claims In Syria” is categorized as “world”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.